The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
State of the art paper Tumor necrosis factor inhibitors – state of knowledge
Open accessAbstract
Tumor necrosis factor (TNF) is considered a major proinflammatory cytokine, affecting various aspects of the immune reaction. All five TNF inhibitors currently available on the market (i.e., etanercept, infliximab, adalimumab, certolizumab and golimumab) are top sellers, although indicated only in autoimmune diseases, including rheumatoid arthritis, Crohn's disease and psoriasis. This article briefly discusses the background and place for TNF inhibitors in modern therapy. The main safety aspects of TNF inhibitor administration are described in particular, with special consideration of the available meta-analyses. Finally, perspectives on the next-generation TNF inhibitors and their use in the clinic are given.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90746-3 · Cited by 986
The many faces of tumor necrosis factor in stroke
Hallenbeck, J. M. (2002) · Nature Medicine · doi:10.1038/nm1202-1363 · Cited by 367
Maneiro, J. R., Salgado, E., Gomez-Reino, J. J., & Carmona, L. (2012) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2011.12.006 · Cited by 59 · cited 1×
“However, the authors conclude that infliximab can cause moderate improvement of selected signs of the disease [19].”
Background
Cited by
Jang, D.-I., Lee, A.-H., Shin, H.-Y., Song, H.-R., Park, J.-H., Kang, T.-B., Lee, S.-R., & Yang, S.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052719 · Cited by 1,694
Rheumatoid Arthritis: A Brief Overview of the Treatment
Bullock, J., Rizvi, S. A. A., Saleh, A. M., Ahmed, S. S., Do, D. P., Ansari, R. A., & Ahmed, J. (2018) · Medical Principles and Practice · doi:10.1159/000493390 · Cited by 776
Metadata
- Authors
- Lis, K., Kuzawińska, O., & Bałkowiec-Iskra, E.
- Venue
- Archives of Medical Science
- Publisher
- Termedia Sp. z.o.o.
- Published
- 2014
- Volume
- 6
- Issue
- 6
- Pages
- 1175-1185
- ISSN
- 1734-1922 (ISSN-L)
- OpenAlex
- W1597227996
- Cited by
- 186
- References
- 3
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: State of the art paper Tumor necrosis factor inhibitors – state of knowledge. https://app.cochat.ai/papers/10.5114/aoms.2014.47827
- The paper
- Lis, K., Kuzawińska, O., & Bałkowiec-Iskra, E. (2014). State of the art paper Tumor necrosis factor inhibitors – state of knowledge. Archives of Medical Science. https://doi.org/10.5114/aoms.2014.47827
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.